AAD Clinical Guidelines
American Academy of Dermatology practice guidelines for psoriasis, atopic dermatitis, hidradenitis suppurativa, and alopecia areata — the primary evidence-based standard for US dermatology practice.
FDA Prescribing Information
Official FDA-approved labels for every biologic, JAK inhibitor, and TYK2 inhibitor in the tool — authoritative source for approved indications, dosing schedules, contraindications, and black box warnings.
Landmark Clinical Trials
Phase 3 registration trials published in NEJM, Lancet, and JAAD including SOLO 1&2, ERASURE/FIXTURE, BE SURE, VOYAGE, UltIMMa, BRAVE-AA, TRuE-V, PIONEER, LIBERTY-BP, and others.
DermSquared Biologics Tool v9
Brownstone & Lebwohl (October 2025) — quick reference chart for approved biologic dosing across psoriasis, HS, AD, PN, CSU, and BP. Used as a cross-reference for dosing accuracy.
AAAAI / EAACI Guidelines
International urticaria guidelines used for chronic spontaneous urticaria biologic selection, including omalizumab and dupilumab positioning.
UpToDate
Evidence-based clinical decision support used to cross-reference treatment algorithms for psoriasis, atopic dermatitis, and other conditions covered in this tool.
Content is reviewed against current literature and updated periodically. DermRx is intended for clinical decision support and educational purposes only — not a substitute for clinical judgment or institutional prescribing guidelines. Clinicians should consult primary sources and current package inserts before prescribing.